Detection of galectin-3 and localization of advanced glycation end products (AGE) in human chronic skin wounds

Histology and Histopathology

Volumn 29, Issue 2, 2014, Pages 251-258

  Pepe, Daniel ^a   Elliott, Christopher G ^a   Forbes, Thomas L ^b   Hamilton, Douglas W ^a  

^a WESTERN UNIVERSITY   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Advanced glycation end product; Chronic wounds; Diabetes; Galectin 3; Wound repair

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GALECTIN 3;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; INJURY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SKIN; SKIN DISEASE; VERY ELDERLY; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GALECTIN 3; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; SKIN; SKIN DISEASES; WOUND HEALING; WOUNDS AND INJURIES;

EID: 84892711074     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Alikhani Z., Alikhani M., Boyd C.M., Nagao K., Trackman P.C. and Graves D.T. (2005). Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J. Biol. Chem. 280, 12087-12095.
2. Cao Z., Said N., Amin S., Wu H.K., Bruce A., Garate M., Hsu D.K., Kuwabara I., Liu F.T. and Panjwani N. (2002). Galectins-3 and -7, but not galectin-1, play a role in re-epithelialization of wounds. J. Biol. Chem. 277, 42299-42305.
3. Dorai T., Fishman A.I., Ding C., Batinic-Haberle I., Goldfarb D.S. and Grasso M. (2011). Amelioration of renal ischemia-reperfusion injury with a novel protective cocktail. J. Urol. 186, 2448-2454.
4. Elliott C.G. and Hamilton D.W. (2011). Deconstructing fibrosis research: Do pro-fibrotic signals point the way for chronic dermal wound regeneration? J. Cell Commun. Signal. 5, 301-15.
5. Fernandes Bertocchi A.P., Campanhole G., Wang P.H., Goncalves G.M., Damiao M.J., Cenedeze M.A., Beraldo F.C., de Paula Antunes, Teixeira V., Dos Reis M.A., Mazzali M., Pacheco-Silva A. and Câmara N.O. (2008). A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl. Int. 21, 999-1007.
6. Gal P., Vasilenko T., Kostelnikova M., Jakubco J., Kovac I., Sabol F., Andre S., Kaltner H., Gabius H.J. and Smetana K. Jr (2011). Open wound healing in vivo: Monitoring binding and presence of Adhesion/Growth-regulatory galectins in rat skin during the course of complete re-epithelialization. Acta Histochem. Cytochem. 44, 191-199.
7. Hu H., Han C.M., Hu X.L., Ye W.L., Huang W.J. and Smit A.J. (2012). Elevated skin autofluorescence is strongly associated with foot ulcers in patients with diabetes: A cross-sectional, observational study of chinese subjects. J. Zhejiang Univ. Sci. B. 13, 372-377.
8. Iacobini C., Menini S., Oddi G., Ricci C., Amadio L., Pricci F., Olivieri A., Sorcini M., Di Mario U., Pesce C. and Pugliese G. (2004). Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: Evidence for a protective role of galectin-3 as an AGE receptor. FASEB J. 18, 1773-1775.
9. Jaksa PJ. and Mahoney J.L. (2010). Quality of life in patients with diabetic foot ulcers: Validation of the cardiff wound impact schedule in a canadian population. Int. Wound. J. 7, 502-507.
10. James R.T., Young K., Mustard C.A. and Blanchard J. (1998). The health of Canadians with diabetes. Health Reports. Vol. 9, no. 3. Winter. Statistics Canada Catalogue no. 82-003. pages 47-52. http://studies-etudes/82-003/archive/1997/3477-eng.pdf (accessed May 10, 2010).
11. Konigshoff M. and Rojas M. (2012). Galectin-3: The bridge over troubled waters. Am. J. Respir. Crit. Care Med. 185, 473-475.
12. Larsen L., Chen H.Y., Saegusa J. and Liu F.T. (2011). Galectin-3 and the skin. J. Dermatol. Sci. 64, 85-91.
13. Liu F.T. and Rabinovich G.A. (2010). Galectins: Regulators of acute and chronic inflammation. Ann. N. Y. Acad. Sci. 1183, 158-182.
14. Lu Y., Liu T., Li H. and Pi G. (2008). Histological evaluation of direct pulp capping with a self-etching adhesive and calcium hydroxide on human pulp tissue. Int. Endod. J. 41, 643-650.
15. Mackie E.J. and Tucker R.P. (1999). The tenascin-C knockout revisited. J. Cell. Sci. 112, 3847-3853.
16. McFarlane S., Glenn J.V., Lichanska A.M., Simpson D.A. and Stitt A.W. (2005). Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium. Br. J. Ophthalmol. 89, 107-112.
17. Midwood K.S., Williams L.V. and Schwarzbauer J.E. (2004). Tissue repair and the dynamics of the extracellular matrix. Int. J. Biochem. Cell Biol. 36, 1031-1037.
18. Niu Y., Xie T., Ge K., Lin Y. and Lu S. (2008). Effects of extracellular matrix glycosylation on proliferation and apoptosis of human dermal fibroblasts via the receptor for advanced glycosylated end products. Am. J. Dermatopathol. 30, 344-351.
19. Okamura D.M., Pennathur S., Pasichnyk K., Lopez-Guisa J.M., Collins S., Febbraio M., Heinecke J. and Eddy A.A. (2009). CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J. Am. Soc. Nephrol. 20, 495-505.
20. O'Loughlin A., McIntosh C., Dinneen S.F. and O'Brien T. (2010). Review paper: Basic concepts to novel therapies: A review of the diabetic foot. Int. J. Low Extrem Wounds 9, 90-102.
21. Puthenedam M., Wu F., Shetye A., Michaels A., Rhee K.J. and Kwon J.H. (2011). Matrilysin-1 (MMP7) cleaves galectin-3 and inhibits wound healing in intestinal epithelial cells. Inflamm. Bowel Dis. 17, 260-267.
22. Rabinovich G.A., Rubinstein N. and Toscano M.A. (2002). Role of galectins in inflammatory and immunomodulatory processes. Biochim. Biophys. Acta 1572, 274-284.
23. Rubinstein N., Ilarregui J.M., Toscano M.A. and Rabinovich G.A. (2004). The role of galectins in the initiation, amplification and resolution of the inflammatory response. Tissue Antigens 64, 1-12.
24. Saravanan C., Liu F.T., Gipson I.K. and Panjwani N. (2009). Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on alpha3beta1 integrin. J. Cell. Sci. 122, 3684-3693.
25. Singh N., Armstrong D.G. and Lipsky B.A. (2005). Preventing foot ulcers in patients with diabetes. JAMA 293, 217-228.
26. Yeh C.H., Sturgis L., Haidacher J., Zhang X.N., Sherwood S.J., Bjercke R.J., Juhasz O., Crow M.T., Tilton R.G. and Denner L. (2001). Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50, 1495-1504.